Scarica l'app Stockscreener
145.55
2.23%
-3.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$148.87
Aprire:
$153.62
Volume 24 ore:
14.92M
Relative Volume:
1.00
Capitalizzazione di mercato:
$58.11B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-17.87
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+5.48%
1M Prestazione:
+155.40%
6M Prestazione:
+151.82%
1 anno Prestazione:
+499.46%
Intervallo 1D:
$141.52
$154.69
Intervallo di 1 settimana:
$133.85
$156.42
Portata 52W:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
How Is Moderna's Stock Performance Compared to Other Healthcare Stocks - Barchart.com
Alibaba DAMO Academy's Liver Cancer AI Model Tops Nature Medicine; Clinical Trial Catches 15 Missed Diagnoses - finance.biggo.com
Moderna Expands mRNA Territory Beyond Personalized Cancer Vaccines to Universal Shots and In Vivo CAR-T - finance.biggo.com
Moderna Moves Beyond Personalized Cancer Vaccines to Universal Shot - Seoul Economic Daily
Moderna Inc. stock holds steady as investors watch vaccine revenue and oncology pipeline - AD HOC NEWS
MRNA Looks 503.7% Overvalued on GF Value™ - GuruFocus
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It - MarketBeat
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.) - Yahoo Finance
AlphaGrep UK Ltd Invests $568,000 in Moderna, Inc. $MRNA - MarketBeat
Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakABC News - ABC News - Breaking News, Latest News and Videos
MRNA Looks 503.4% Overvalued on GF Value™ - GuruFocus
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks - Seeking Alpha
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation - finance.biggo.com
Step Capital Management Pte. Ltd. Has $48.67 Million Stake in Moderna, Inc. $MRNA - MarketBeat
22,477 Shares in Moderna, Inc. $MRNA Acquired by AXQ Capital LP - MarketBeat
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. - WSJ
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes? - Yahoo Finance
Moderna's mRNA flu vaccine, mFlusiva, offers option for adults 50-64 with potential benefits over traditional shot - ABC7 New York
Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run - Yahoo Finance
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run? - Yahoo Finance
Healthcare Stocks To Watch TodaySeptember 4th - MarketBeat
Moderna stock falls after Rothschild Redburn downgrade - AD HOC NEWS
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Moderna (MRNA) Stock Is Down Today - Yahoo Finance
Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says - CNBC TV18
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? - The Globe and Mail
Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets - FXEmpire
Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock - MarketBeat
Moderna (MRNA) CFO has 2,475 stock units vest in Sept. award - Stock Titan
Moderna (MRNA) legal chief trades stock under 10b5-1 plan - Stock Titan
MRNA Looks 500.3% Overvalued on GF Value™ - GuruFocus
Can Moderna reclaim 52-week highs after pullback, or have best levels been seen? - Investing.com
Moderna stock slips as Rothschild downgrades (MRNA:NASDAQ) - Seeking Alpha
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop - Barron's
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK? - Yahoo Finance
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Gap Down on Analyst Downgrade - MarketBeat
MRNA Downgraded by Rothschild & Co -- Price Target Raised to $81 - GuruFocus
Rothschild & Co Redburn Downgrades Moderna (NASDAQ:MRNA) to Sell - MarketBeat
Moderna: Massive Asymmetry About What The mRNA Is! (NASDAQ:MRNA) - Seeking Alpha
Rothschild Redburn downgrades Moderna stock on valuation concerns By Investing.com - Investing.com India
A cancer vaccine is closer than ever - themalaysianreserve.com
Jim Cramer Explains Why Heavily Shorted Moderna (MRNA) Has Room to Run - Yahoo Finance
MRNA Stock Pulls Back to $150 as Moderna Faces Key Test Ahead - FXLeaders
Why Moderna's Cancer Vaccine Matters To Investors - ETF Database
Moderna Stock Moves Lower Wednesday: What's Going On? - Benzinga
Moderna (MRNA) Stock Climbs Nearly 4% Following Melanoma Trial Success and Vaccine Approval - Blockonomi
Merck, Moderna report positive Phase 3 results for personalized melanoma vaccine - BusinessMirror
Cathie Wood Sells $15.6 Million of Tempus AI Stock After Merck-Moderna Trial Win, Ark Keeps Selling AMD Shares - Benzinga
Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat? - Yahoo Finance
Moderna (MRNA) Completes $3 Billion Zero-Coupon Convertible Seni - GuruFocus
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Sep 01 '26 |
Sale |
139.95 |
3,471 |
485,766 |
74,129 |
1.93%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):